Claims for Patent: 7,744,910

Summary for Patent: 7,744,910

Title:	Compounds and compositions for delivering active agents
Abstract:	Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
Inventor(s):	Gschneidner; David (Thornwood, NY), Leone-Bay; Andrea (Ridgefield, CT), Wang; Eric (Ellicott City, MD), Errigo; Lynn (Port Chester, NY), Ho; Koc-Kan (Mount Kisco, NY), Press; Jeffrey Bruce (Brewster, NY), Wang; Nai Fang (Long Island City, NY), Tang; Pingwah (Elmsford, NY)
Assignee:	Emisphere Technologies, Inc. (Cedar Knolls, NJ)
Application Number:	11/531,602
Patent Claims:	1. A compound represented by the formula: ##STR00008## or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 wherein the pharmaceutically acceptable salt is sodium salt. 3. A composition comprising: (A) at least one biologically active agent; and (B) the compound of claim 1. 4. The compound of claim 3 wherein the pharmaceutically acceptable salt is sodium salt. 5. The composition of defined in claim 3, wherein said biologically active agent comprises at least one protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 6. The composition of claim 5, wherein said biologically active agent comprises a protein, polypeptide or peptide. 7. The composition of claim 5, wherein said biologically active agent comprises a mucopolysaccharide. 8. The composition of claim 3, wherein said biologically active agent is selected from the group consisting of: growth hormone, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials, anti-fungal agents; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof. 9. The composition of claim 8, wherein said biologically active agent is selected from a growth hormone, interferon, insulin, heparin, cromolyn sodium, an antigen, an anti-microbial agent, calcitonin, parathyroid hormone, erythropoietin, and combinations thereof. 10. The composition of claim 9, wherein said growth hormone is selected from human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, or a combination thereof. 11. The composition of claim 8, wherein said biologically active agent is interferon. 12. The composition of claim 8, wherein said biologically active agent is insulin. 13. The composition of claim 8, wherein said insulin is selected from porcine insulin, bovine insulin, human insulin, and human recombinant insulin. 14. The composition of claim 8, wherein said biologically active agent is heparin. 15. The composition of claim 14, wherein said heparin is selected from low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, heparinoids, dermatans, chondroitins, or a combination thereof. 16. The composition of claim 15, wherein said biologically active agent is low molecular weight heparin. 17. The composition of claim 8, wherein said biologically active agent is cromolyn sodium. 18. The composition of claim 17, wherein said cromolyn sodium is selected from sodium chromoglycate, disodium chromoglycate or a combination thereof. 19. The composition of claim 8, wherein said biologically active agent is an antigen. 20. The composition of claim 8, wherein said biologically active agent is an anti-microbial agent. 21. The composition of claim 8, wherein said biologically active agent is a calcitonin. 22. The composition of claim 21, wherein said calcitonin is selected from salmon calcitonin, eel calcitonin, human calcitonin or a combination thereof. 23. The composition of claim 8, wherein said biologically active agent is parathyroid hormone. 24. The composition of claim 8, wherein said biologically active agent is erythropoietin. 25. A dosage unit form comprising (A) a composition as defined in claim 3; and (B) (a) an excipient (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof. 26. The dosage unit form of claim 25 wherein the pharmaceutically acceptable salt is the sodium salt. 27. The dosage unit form of claim 25, comprising a powder. 28. The dosage unit form of claim 25 comprising a tablet. 29. The dosage unit form of claim 25 comprising a capsule. 30. The dosage unit form of claim 25 comprising a liquid. 31. The dosage unit form of claim 25, wherein said biologically active agent comprises at least one protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 32. The dosage unit form of claim 31, wherein said biologically active agent comprises a protein, polypeptide, or peptide. 33. The dosage unit form of claim 31, wherein said biologically active agent comprises a mucopolysaccharide. 34. The dosage unit form of claim 25, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol, olive oil or any combination thereof. 35. The dosage unit form of claim 25, wherein said biologically active agent is selected from the group consisting of: growth hormone, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials, anti-fungal agents; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof. 36. The dosage unit form of claim 35, wherein said biologically active agent is selected from a growth hormone, interferon, insulin, heparin, cromolyn sodium, an antigen, an anti-microbial agent, calcitonin, parathyroid hormone, erythropoietin, and combinations thereof. 37. The dosage unit form of claim 35, wherein said growth hormone is selected from human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, or a combination thereof. 38. The dosage unit form of claim 35, wherein said biologically active agent is interferon. 39. The dosage unit form of claim 35, wherein said biologically active agent is insulin. 40. The dosage unit form of claim 39, wherein said insulin is selected from porcine insulin, bovine insulin, human insulin, and human recombinant insulin. 41. The dosage unit form of claim 35, wherein said biologically active agent is heparin. 42. The composition of claim 41, wherein said heparin is selected from low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, heparinoids, dermatans, chondroitins, or a combination thereof. 43. The dosage unit form of claim 42, wherein said biologically active agent is low molecular weight heparin. 44. The dosage unit form of claim 35, wherein said biologically active agent is cromolyn sodium. 45. The dosage unit form of claim 44, wherein said cromolyn sodium is selected from sodium chromoglycate, disodium chromoglycate or a combination thereof. 46. The dosage unit form of claim 35, wherein said biologically active agent is an antigen. 47. The dosage unit form of claim 35, wherein said biologically active agent is an anti-microbial agent. 48. The dosage unit form of claim 35, wherein said biologically active agent is calcitonin. 49. The dosage unit form of claim 35, wherein said calcitonin is selected from salmon calcitonin, eel calcitonin, human calcitonin or a combination thereof. 50. The dosage unit form of claim 35, wherein said biologically active agent is parathyroid hormone. 51. The dosage unit form of claim 35, wherein said biologically active agent is erythropoietin. 52. A method for administering a biologically active agent to an animal, said method comprising administering to said animal the composition of claim 3. 53. The method of claim 52 wherein the pharmaceutically acceptable salt is the sodium salt. 54. The method of claim 52, wherein said biologically active agent is administered by a route selected from: oral, intranasal, sublingual, intraduodenal, subcutaneous, buccal, intracolonic, rectal, vaginal, mucosal, pulmonary, transdermal, intradermal, parenteral, intravenous, intramuscular and intraocular. 55. The method of claim 52, wherein said biologically active agent is administered by the oral route. 56. The method of claim 52, wherein said biologically active agent comprises at least one protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 57. The method of claim 56, wherein said biologically active agent comprises a protein, polypeptide, or peptide. 58. The method of claim 56, wherein said biologically active agent comprises a mucopolysaccharide. 59. The method of claim 52, wherein said biologically active agent is selected from the group consisting of: growth hormone, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials, anti-fungal agents; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof. 60. The method of claim 59, wherein said biologically active agent is selected from a growth hormone, interferon, insulin, heparin, cromolyn sodium, an antigen, an anti-microbial agent, calcitonin, parathyroid hormone, erythropoietin, and combinations thereof. 61. The method of claim 59, wherein said growth hormone is selected from human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, or a combination thereof. 62. The method of claim 59, wherein said biologically active agent is interferon. 63. The method of claim 59, wherein said biologically active agent is insulin. 64. The method of claim 63, wherein said insulin is selected from porcine insulin, bovine insulin, human insulin, and human recombinant insulin. 65. The method of claim 59, wherein said biologically active agent comprises heparin. 66. The method of claim 65, wherein said heparin is selected from low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, heparinoids, dermatans, chondroitins, or a combination thereof. 67. The method of claim 66, wherein said biologically active agent is low molecular weight heparin. 68. The method of claim 59, wherein said biologically active agent is cromolyn sodium. 69. The method of claim 68, wherein said cromolyn sodium is sodium chromoglycate, disodium chromoglycate or a combination thereof. 70. The method of claim 59, wherein said biologically active agent is an antigen. 71. The method of claim 43, wherein said biologically active agent is an anti-microbial agent. 72. The method of claim 43, wherein said biologically active agent is calcitonin. 73. The method of claim 43, wherein said calcitonin is selected from salmon calcitonin, eel calcitonin, human calcitonin or a combination thereof. 74. The method of claim 43, wherein said biologically active agent is parathyroid hormone. 75. The method of claim 43, wherein said biologically active agent is erythropoietin. 76. A method for preparing a composition, said method comprising mixing: (A) at least one biologically active agent; (B) at least one compound as defined in claim 1; and (C) optionally, a dosing vehicle. 77. The method of claim 76 wherein the pharmaceutically acceptable salt is sodium salt. 78. The method of claim 76, wherein said biologically active agent comprises at least one protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 79. The method of claim 78, wherein said biologically active agent comprises a protein, polypeptide, or peptide. 80. The method of claim 78, wherein said biologically active agent comprises a mucopolysaccharide. 81. The method of claim 76, wherein said biologically active agent is selected from the group consisting of: growth hormone, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials, anti-fungal agents; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof.

Details for Patent 7,744,910

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2018-08-07
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2018-08-07
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2018-08-07
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2018-08-07
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2018-08-07